Researchers Uncover Mechanism of Nirmatrelvir Resistance in SARS-CoV-2

Strategic Insights -

A recent study published in Science Advances has revealed a key mechanism of resistance to the antiviral medication nirmatrelvir (NIR) in the SARS-CoV-2 protease. The research, conducted by a team of scientists at Emory University, found that a specific mutation in the SARS-CoV-2 nsp5 protease, E166V, confers strong resistance to NIR in passaging and clinical samples. This discovery highlights the importance of developing second-generation antivirals that can overcome this resistance mechanism.

Key Takeaways:

  • The E166V mutation in the SARS-CoV-2 nsp5 protease confers strong resistance to the antiviral medication nirmatrelvir (NIR) in passaging and clinical samples.
  • The mutation drastically decreases the fitness of the SARS-CoV-2 virus in replicons, particularly in the Washington (WA1) strain.
  • The research team found that the E166V mutation disrupts the covalent binding of NIR to the catalytic Cys145, leading to high resistance in BA.1 and WA1 replicons.
  • The study suggests that a steric clash between the rigid, bulky NIR tert-butyl group and the beta-branched Val166 is responsible for the resistance.
  • The researchers propose that strategic flexibility is a strategy to design second-generation antivirals that can overcome this resistance mechanism.
  • The study was supported by the National Institutes of Health (NIH) and was conducted by a team of scientists at Emory University, including Shuiyun Lan, Grace Neilsen, and Stefan G. Sarafianos.

Statistics:

  • The E166V mutation confers 20- to 2-fold decrease in fitness of the SARS-CoV-2 virus in replicons.
  • The resistance mechanism is caused by a steric clash between the NIR tert-butyl group and the beta-branched Val166.
  • The research team found that the E166V mutation is responsible for high resistance in BA.1 and WA1 replicons.

Sources:

  • NewsRx. Findings from Emory University Update Understanding of COVID-19 (Strategy To Overcome a Nirmatrelvir Resistance Mechanism In the Sars-cov-2 Nsp5 Protease). Medical Letter on the CDC & FDA. July 6, 2025; p 45.
  • Lan, S., Neilsen, G., Slack, R. L., Lorson, Z. C., Castaner, A. E., Lee, R., ... & Sarafianos, S. G. (2025). Strategy To Overcome a Nirmatrelvir Resistance Mechanism In the Sars-cov-2 Nsp5 Protease. Science Advances, 11(23).